Scream 7 debuted strongly at the box office even as protests over Melissa Barrera’s firing and heated industry debates cast a long shadow
Scream 7 opened to surprisingly strong box office numbers despite months of protests and an organized boycott campaign after Melissa Barrera was removed from the sequel. The film pulled in $97.2 million worldwide on release — the biggest debut in the franchise and a new record for Paramount.
A noisy controversy, a big opening
The premiere at Paramount Studios on February 25, 2026, became the focal point for demonstrators. Activist groups including Entertainment Labor for Palestine, CodePink LA and Jewish Voice for Peace-Los Angeles turned out, and online calls to boycott the film circulated for weeks after Barrera’s departure, which followed her social-media comments about Gaza. Yet the film’s opening suggests that anger and activism didn’t entirely translate into diminished ticket sales.
That contradiction raises the central question: does a powerful opening weekend tell the whole story about a movie’s commercial future? Short answer: no. A big debut reflects marketing muscle, franchise recognition and curiosity — but it doesn’t guarantee lasting audience enthusiasm or healthy downstream revenue.
Opening weekend vs. long-term health
Paramount’s strategy — including a review embargo that fueled presales before critics weighed in — helped accumulate early ticket sales. Those numbers often measure curiosity more than endorsement: fans show up to see how a franchise evolves, and casual viewers are less likely to follow online controversies closely.
But there are warning signs. Early critical reaction hasn’t been kind: Scream 7 sits around 32 percent on Rotten Tomatoes and 36 on Metacritic. If critics’ views match audience word-of-mouth, the film could front-load its earnings and then tumble, especially in markets where the protests resonated. What will matter now are week-to-week drops, regional performance and how the title performs after theaters — streaming deals, rentals, and international licensing will reveal the fuller picture.
How controversy changes the calculus
The dispute around Scream 7 went beyond fan squabbles and touched broader debates over free speech, labor solidarity and corporate responsibility. Barrera’s firing — prompted by social-media language Spyglass called unacceptable — prompted departures elsewhere on the project and intensified unrest among parts of the fanbase and industry. The premiere itself saw both protests and counterprotests. For some red-carpet attendees the demonstrations were a backdrop; for others they became the story.
Studios have to weigh these dynamics carefully. Controversy can be absorbed as a short-term cost, but it often raises marketing expenses, complicates distributor relationships and can limit international rollout. Some franchises shrug it off and push ahead; others pause, retool or adapt release strategies to reduce exposure.
Advertising, retention and the franchise’s future
Horror franchises are uniquely positioned to produce big openings on name recognition alone. But sustaining a franchise requires more: repeat viewings, positive audience sentiment and stable exhibitor support. If those fray, so does the business case for sequels. Executives looking at Scream 8 won’t rely on one weekend’s tally — they’ll watch retention, social sentiment, pre-sales for future windows and how eager theaters and international partners are to carry another installment.
Practically, expect production partners to reassess timelines, talent contracts and insurance terms. Studios will monitor audience scores, second-week declines and post-theatrical licensing to decide whether to greenlight more installments or retool the series’ creative direction.
What to watch next
The next few weeks will be telling. Key indicators:
– Weekend-to-weekend hold percentage and per-theater averages.
– Audience ratings and social-media conversation — does chatter shift from controversy to the film itself?
– Downstream interest: streaming deals, international licensing and rental performance.
If Scream 7 shows healthy holds and positive audience word-of-mouth, the franchise can weather the controversy. If not, this opening may be remembered as a front-loaded spike rather than a durable rebound. The studio’s challenge now is turning curiosity into sustained support while managing the real costs controversy can impose on marketing, distribution and future creative choices. The numbers that follow this weekend will matter far more than the headline gross.